GSK241108C34000
- 0.00
- 0.000.00%
GlaxoSmithKline Newsroom
GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49
Dermatology Treatment and Care Market Research 2024-2030 Featuring Novartis, Pfizer, Amgen, GlaxoSmithKline, F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Merck & Co, Bayer, and Sanofi - ResearchAndMarkets.com
M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More
GSK Cut to Neutral From Buy by Guggenheim
GSK Analyst Ratings
GSK Downgraded at Guggenheim After Q3 Sales Drop
Guggenheim Downgrades GlaxoSmithKline(GSK.US) to Hold Rating
Express News | JPMorgan: Downgraded glaxosmithkline's target price from 1550 pence to 1440 pence.
GlaxoSmithKline To Go Ex-Dividend On November 15th, 2024 With 0.38905 USD Dividend Per Share
October 30th (Eastern Time) - $GlaxoSmithKline(GSK.US)$ is trading ex-dividend on November 15th, 2024.Shareholders of record on November 15th, 2024 will receive 0.38905 USD dividend per share on
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
GSK Plc (GSK) Q3 2024 Earnings Call Transcript
USDA Says H5N1 Bird Flu Detected In Swine For The First Time In U.S. In Oregon Backyard Farm; There Is No Concern About Safety Of The Nation's Pork Supply As A Result Of This Finding On HPAI Detections In Oregon Backyard Farm
USDA To Begin Bulk Milk Testing For Bird Flu Nationwide Following Pressure From Industry And Veterinary Groups; New Effort Aims To Curb Rapid Spread Among Dairy Herds
6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d
European Equities Traded in the US as American Depositary Receipts Down Sharply in Wednesday Trading
GSK's 3Q Results Are a Mixed Bag -- Market Talk
U.S. stock market anomaly | glaxosmithkline fell more than 3.8% Q3 revenue year-on-year decline of 2% lower than expected
On October 30th, GlaxoSmithKline (GSK.US) fell more than 3.8%, closing at $36.7. On the news front, GlaxoSmithKline's revenue in the third quarter was £8.012 billion, a 2% year-on-year decrease, lower than the analyst's expected £8.1 billion; the earnings per share after deducting some items was 49.7 pence, higher than the analyst's forecast of 44 pence. Vaccine sales in the period decreased by 18% to £2.65 billion. (Glory)
Sector Update: Health Care Stocks Decline Premarket Wednesday
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
GSK Shares Are Trading Lower After the Company Reported Mixed Q3 Financial Results.